JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 126 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $123,125 | +176.7% | 66,554 | +66.0% | 0.00% | – |
| Q4 2022 | $44,497 | -86.8% | 40,087 | -72.2% | 0.00% | -100.0% |
| Q3 2022 | $338,000 | +3.0% | 144,287 | +33.5% | 0.00% | 0.0% |
| Q2 2022 | $328,000 | -60.9% | 108,115 | -12.4% | 0.00% | -60.0% |
| Q1 2022 | $838,000 | -11.2% | 123,351 | +9.1% | 0.01% | 0.0% |
| Q4 2021 | $944,000 | +20.3% | 113,065 | +7.0% | 0.01% | +25.0% |
| Q3 2021 | $785,000 | +24.4% | 105,696 | +13.8% | 0.00% | +33.3% |
| Q2 2021 | $631,000 | +4407.1% | 92,867 | +6693.5% | 0.00% | – |
| Q1 2021 | $14,000 | +40.0% | 1,367 | 0.0% | 0.00% | – |
| Q4 2020 | $10,000 | -58.3% | 1,367 | -52.8% | 0.00% | – |
| Q3 2020 | $24,000 | +60.0% | 2,897 | +29.7% | 0.00% | – |
| Q2 2020 | $15,000 | 0.0% | 2,233 | -31.0% | 0.00% | – |
| Q1 2020 | $15,000 | -46.4% | 3,236 | 0.0% | 0.00% | – |
| Q4 2019 | $28,000 | +154.5% | 3,236 | 0.0% | 0.00% | – |
| Q3 2019 | $11,000 | +266.7% | 3,236 | +422.8% | 0.00% | – |
| Q2 2019 | $3,000 | -62.5% | 619 | +6.5% | 0.00% | – |
| Q2 2017 | $8,000 | -94.3% | 581 | -90.9% | 0.00% | -100.0% |
| Q1 2017 | $141,000 | – | 6,413 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |